Metropolitan Life Insurance Co. NY trimmed its position in Gilead Sciences (NASDAQ:GILD) by 63.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 242,547 shares of the biopharmaceutical company’s stock after selling 415,730 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Gilead Sciences were worth $17,376,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vident Investment Advisory LLC lifted its position in shares of Gilead Sciences by 40.5% during the 4th quarter. Vident Investment Advisory LLC now owns 68,800 shares of the biopharmaceutical company’s stock valued at $4,929,000 after acquiring an additional 19,833 shares during the last quarter. Financial Advocates Investment Management acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $607,000. Laurel Wealth Advisors Inc. lifted its position in shares of Gilead Sciences by 12.5% during the 4th quarter. Laurel Wealth Advisors Inc. now owns 9,726 shares of the biopharmaceutical company’s stock valued at $696,000 after acquiring an additional 1,080 shares during the last quarter. Hoylecohen LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $6,202,000. Finally, Platinum Investment Management Ltd. lifted its position in shares of Gilead Sciences by 5.0% during the 4th quarter. Platinum Investment Management Ltd. now owns 3,044,930 shares of the biopharmaceutical company’s stock valued at $218,138,000 after acquiring an additional 145,300 shares during the last quarter. Hedge funds and other institutional investors own 78.35% of the company’s stock.
Several analysts have issued reports on the stock. Leerink Swann reissued a “market perform” rating and set a $80.00 target price (down from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Thursday. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Wednesday, January 3rd. Finally, Wells Fargo raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $79.02 to $96.00 in a research note on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $88.65.
In related news, CFO Robin L. Washington sold 5,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the completion of the sale, the chief financial officer now directly owns 23,749 shares in the company, valued at $1,907,282.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Francis Cogan sold 5,833 shares of the company’s stock in a transaction on Friday, April 13th. The stock was sold at an average price of $75.56, for a total transaction of $440,741.48. Following the completion of the sale, the director now owns 58,452 shares of the company’s stock, valued at $4,416,633.12. The disclosure for this sale can be found here. Insiders sold 308,600 shares of company stock valued at $24,328,226 over the last quarter. 1.30% of the stock is currently owned by corporate insiders.
NASDAQ GILD opened at $73.70 on Friday. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $89.54. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74. The firm has a market capitalization of $97,058.59, a PE ratio of 8.61, a P/E/G ratio of -1.68 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same period in the prior year, the business posted $2.70 earnings per share. Gilead Sciences’s revenue for the quarter was down 18.7% compared to the same quarter last year. sell-side analysts predict that Gilead Sciences will post 6.32 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Investors of record on Friday, March 16th were issued a $0.57 dividend. The ex-dividend date was Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 3.09%. Gilead Sciences’s dividend payout ratio is currently 26.64%.
COPYRIGHT VIOLATION NOTICE: “Gilead Sciences (GILD) Shares Sold by Metropolitan Life Insurance Co. NY” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/22/gilead-sciences-gild-shares-sold-by-metropolitan-life-insurance-co-ny.html.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.